OVERVIEW
Codipront 90ml Codeine Syrup
Codipront 90ml Codeine Syrup, 2.22 mg/ml + 0.733 mg/ml, syrup
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
935 – 1 205 mg of codeine-poly (styrene, divinylbenzene)-sulfonate,
equivalent to 200 mg of codeine.
148.5 – 194 mg of phenyltoloxamine-poly (styrene,
divinylbenzene)-sulfonate, equivalent to 66 mg of
phenyltoloxamine.
Excipient(s) with known effect
Each millilitre of syrup contains 2.3 mg of methyl
parahydroxybenzoate;
Each millilitre of syrup contains 1.0 mg of propyl
parahydroxybenzoate;
Each millilitre of syrup contains 383.34 mg of sorbitol (as sorbitol
70% solution);
Each millilitre of syrup contains 0.87 mg of potassium (as potassium
chloride).
Each millilitre of syrup contains 0.36 mg of sodium.
For the full list of excipients, see section 6.1.
PHARMACEUTICAL FORM
Syrup
THERAPEUTIC INDICATIONS
Codipront is recommended for the symptomatic relief of acute dry
irritating cough in adults and
children over 12 years of age.
POSOLOGY AND METHOD OF ADMINISTRATION
Posology and duration of treatment depend on the basic disease, as
well as on the intensity and
frequency of cough. The patient should follow the attending physician
instructions.
Duration of treatment:
The duration of treatment is defined by the doctor
Codipront 90ml Codeine Syrup
